Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s007870200023 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Advancing pancreatic cancer research and therapeutics: the transformative role of organoid technology.
Exp Mol Med
January 2025
Department of Microbiology and Molecular Genetics, University of California, Davis, Davis, CA, 95616, USA.
Research on pancreatic cancer has transformed with the advent of organoid technology, providing a better platform that closely mimics cancer biology in vivo. This review highlights the critical advancements facilitated by pancreatic organoid models in understanding disease progression, evaluating therapeutic responses, and identifying biomarkers. These three-dimensional cultures enable the proper recapitulation of the cellular architecture and genetic makeup of the original tumors, providing insights into the complex molecular and cellular dynamics at various stages of pancreatic ductal adenocarcinoma (PDAC).
View Article and Find Full Text PDFIntestinal schistosomiasis in remote areas of Southwest Ethiopia, a target region for large-scale mass drug administration.
Sci Rep
January 2025
Aklilu Lemma Institute of Pathobiology, Addis Ababa University, Addis Ababa, Ethiopia.
As 2030 approaches, the World Health Organization's due date for ending intestinal schistosomiasis as a public health problem in all endemic areas, understanding the current trends in the burden of schistosomiasis among schoolchildren in endemic areas is critical for monitoring the progress, identifying areas for improvement, and developing strategies to plan for instant response to mitigate the burden of schistosomiasis. From February to April of 2023, 328 students from three primary schools in Southwest Ethiopia participated in an institution-based cross-sectional study in the detection of Schistosoma mansoni. Intestinal schistosomiasis was identified among 242 school children, with a rate of infection of 73.
View Article and Find Full Text PDFReplacement of fishmeal with Quinoa Husk (Chenopodium quinoa) for mitigating multiple stresses in Pangasianodon Hypophthalmus.
Sci Rep
January 2025
ICAR-National Institute of Abiotic Stress Management, Baramati, Pune, 413115, India.
The fishmeal is boon for aquaculture production in this recent pollution and climate change era. However, the demand of fishmeal is enhancing in many folds which needs to find alternative to fishmeal in cheap price. The present investigation addresses these issues with quinoa husk (QH).
View Article and Find Full Text PDFThe structural organisation of pentraxin-3 and its interactions with heavy chains of inter-α-inhibitor regulate crosslinking of the hyaluronan matrix.
Matrix Biol
January 2025
Manchester Cell-Matrix Centre, Division of Cell-Matrix Biology and Regenerative Medicine, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, Manchester M13 9PT, UK; Lydia Becker Institute of Immunology and Inflammation, University of Manchester, Manchester, M13 9PL, United Kingdom. Electronic address:
Pentraxin-3 (PTX3) is an octameric protein, comprised of eight identical protomers, that has diverse functions in reproductive biology, innate immunity and cancer. PTX3 interacts with the large polysaccharide hyaluronan (HA) to which heavy chains (HCs) of the inter-α-inhibitor (IαI) family of proteoglycans are covalently attached, playing a key role in the (non-covalent) crosslinking of HC•HA complexes. These interactions stabilise the cumulus matrix, essential for ovulation and fertilisation in mammals, and are also implicated in the formation of pathogenic matrices in the context of viral lung infections.
View Article and Find Full Text PDFAnakinra improves retention rate of targeted treatments in Erdheim-Chester disease.
Rheumatology (Oxford)
January 2025
Unit of Immunology, Rheumatology, Allergy and Rare Diseases, IRCCS San Raffaele Hospital, Vita-Salute San Raffaele University, Milan, Italy.
Objective: Erdheim-Chester disease (ECD) is a rare non-Langerhans cell histiocytosis that exhibits a wide spectrum of clinical manifestations. The recent identification of activating mutations in the MAPK-ERK pathway in patients with ECD has led to the introduction of targeted therapies. The most commonly used targeted therapies are BRAF- and MEK-inhibitors, which are highly effective but also carry significant toxicity.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!